CD40


Also found in: Acronyms.

CD40

a type I transmembrane protein present on mature B cells, monocytes, dendritic cells, and epithelial cells involved in signal transduction leading to cell activation, proliferation, adhesion, and/or differentiation; expressed in B-cell chronic lymphocytic leukemias, lymphomas, and some carcinomas.
References in periodicals archive ?
APX005M is a novel, humanised investigational monoclonal antibody designed to overcome the systemic immune suppression that typically affects cancer patients through activation of CD40, a co-stimulatory receptor on the antigen presenting cells that is essential for activating both innate and adaptive immunity.
The thermal profile for amplification of CD40 C/T-1 was: 10 minutes initial denaturation at 95AdegC followed by 35 cycles including denaturation at 95AdegC for 45 seconds, annealing at 56AdegC for 1 minute, extension for 1 minute at 72AdegC and ultimate extension was carried out at 72AdegC for 7 minutes.
Therefore I believe there is a gap in our knowledge regarding the therapeutic mode of action of CD40 Abs in humans.
The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40)
Flow cytometry analysis revealed that, compared to the control (0 [micro]g/ml of AGAF), bone marrow- and monocyte-derived DCs with AGAF treatment exhibited higher levels of CD86, CD83, CD80, CD40, and MHC I and II (Fig.
It was found recently that CD40-CD40L (cellular responses mediated by CD40 are triggered by its counter receptor CD40L which also belongs to the TNF gene family) interaction appears to be an active process during orthodontic tooth movement and that orthodontic force induces T-cell activation.
CD40 is a co-stimulatory molecule that is a member of the tumor necrosis factor receptor (TNF-R) family.
Monoclonal Antibodies against CD40 Antigen: Dacetuzumab and Lucatumumab.
A group of researchers led by the University of Pennsylvania's Perelman School of Medicine and Abramson Cancer Center, in collaboration with scientists from the University of Pittsburgh and University of Washington, published results of a clinical trial in which the standard chemotherapy drug for this disease, gemcitabine, was paired with an agonist CD40 antibody, resulting in substantial tumor regressions among some patients with advanced pancreatic cancer.
However, no significant difference was observed in cell proliferation, morphology and phenotype between group A and B, but the mRNA expression levels of surface marker genes, MHC-II, CD40, CD80, CD83 and CD86 were up regulated (<0.